Aspire Biopharma Holdings, Inc. (ASBP) — Financial statements
Income statement, balance sheet, and cash flow for Aspire Biopharma Holdings, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Cost of Revenue | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Gross Profit | -0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | ||||||
| R&D Expenses | 0.92↑540.0% | 0.14↑100.4% | 0.07↓58.9% | 0.18 | 0.00 | |
| General & Administrative Expenses | 18↑471.0% | 3↑130.5% | 1↑37.2% | 0.98↑3413.2% | 0.03 | |
| Selling & Marketing Expenses | 0.79 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 18↑496.5% | 3↑130.5% | 1↑37.2% | 0.98↑3413.2% | 0.03 | |
| Other Expenses | 0.00↑100.0% | -0.14↓100.4% | -0.07↑58.9% | -0.18↓7469.8% | -0.00 | |
| Operating Expenses | 19↑526.5% | 3↑130.5% | 1↑37.2% | 0.98↑3732.6% | 0.03 | |
| Total Costs & Expenses | 19↑526.7% | 3↑130.5% | 1↑37.2% | 0.98↑3732.6% | 0.03 | |
| Operating Results | ||||||
| Operating Income | -19↓526.5% | -3↓130.5% | -1↓37.2% | -0.98↓3731.8% | -0.03 | |
| Depreciation & Amortization | 0.00 | 0.00↓100.0% | 1 | 0.00↓100.0% | 0.03 | |
| EBITDA | -19↓66.2% | -12↓300.7% | 6↑73.8% | 3↑13209.3% | -0.03 | |
| EBIT | -19↓66.2% | -12↓360.4% | 4↑33.9% | 3 | 0.00 | |
| Interest & Other Income | ||||||
| Net Interest Income | -9↓2387.6% | -0.34↓105.9% | 6↑34.4% | 4 | 0.00 | |
| Interest Income | 0.00↓100.0% | 0.55↓90.6% | 6↑34.7% | 4 | 0.00 | |
| Interest Expense | 9↑1056.4% | -0.89↓10048.7% | 0.01 | 0.00 | 0.00 | |
| Non-Operating Income | 0.00↓100.0% | 9↑247.2% | -6↓34.7% | -4 | 0.00 | |
| Other Income / Expenses | -5↑45.7% | -9↓262.8% | 6↑34.4% | 4↑86339900.0% | 0.00 | |
| Income Before Tax | -24↓95.3% | -13↓380.8% | 4↑33.7% | 3↑13210.9% | -0.03 | |
| Income Tax Expense | 0.00↓100.0% | 0.00 | 0.00↓100.0% | 0.00 | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -24↓95.3% | -13↓380.9% | 4↑33.7% | 3↑13210.9% | -0.03 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -24↓95.3% | -13↓380.8% | 4↑33.7% | 3↑13210.9% | -0.03 | |
| Bottom-Line Net Income | -24↓95.3% | -13↓380.8% | 4↑33.7% | 3↑13210.9% | -0.03 | |
| EPS (Basic) | -16.38↑9.9% | -18.17↓295.2% | 9.31↑150.3% | 3.72↑10073.2% | -0.04 | |
| EPS (Diluted) | -16.38↑9.9% | -18.17↓295.2% | 9.31↑150.3% | 3.72↑10073.2% | -0.04 | |
| Weighted Average Shares | 1↑116.7% | 0.69↑43.9% | 0.48↓46.6% | 0.90↑31.6% | 0.68 | |
| Weighted Average Diluted Shares | 1↑116.7% | 0.69↑43.9% | 0.48↓46.6% | 0.90↑31.6% | 0.68 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.